Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
Conditions
Keywords
metastatic
Brief summary
Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other anti-angiogenic drugs. Cabozantinib has been studied or is being study in research studies as a possible treatment for various types of cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. In this research study, the investigators wish to learn if cabozantinib is effective in treating patients with pancreatic neuroendocrine and carcinoid tumors.
Detailed description
Subjects will take cabozantinib orally, once per day, in cycles of 28 days. During each cycle subjects will have the following procedures: * Physical examination, including measurement of weight and vital signs * Questions regarding any side effects * Blood sample (about 1 tablespoon) for routine laboratory tests of blood cell counts, blood chemistries, organ function and blood clotting * Blood sample (about 4 tablespoons) for research test to measure biomarkers to assess the response to study drug * Urine sample for routine urine tests to monitor health On Day 15 (beginning of week 3) during the first 3 cycles: * Physical examination, including measurement of weight and vital signs * Questions regarding any side effects * Blood sample (about 1 tablespoon) for routine laboratory tests of blood cell counts, blood chemistries, organ function and blood clotting * Blood sample (about 4 tablespoons) for research test to measure biomarkers to assess the response to study drug Subjects will receive a CT scan or MRI every two cycles (every two months) to evaluate disease.
Interventions
DRUGCabozantinib
60 mg QD orally in cycles of 28 days
Sponsors
Dana-Farber Cancer Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Locally unresectable or metastatic, histologically-confirmed, carcinoid or pancreatic neuroendocrine tumor. Tumors must be considered well- or moderately-differentiated. Patients with poorly differentiated neuroendocrine carcinoma or cell carcinoma are excluded from the study. * A tumor sample is required for enrollment (except for patients diagnosed \> 7 years ago). * Must have measurable disease by RECIST criteria * Must have evidence of progressive disease within 12 months of study entry * Prior or concurrent therapy with somatostatin analogs is permitted. If on somatostatin/octreotide, must be on a stable dose for at least two months. * Age ≥ 18 years * No major surgery or radiation in the prior 4 weeks prior to enrollment * No prior therapy with cabozantinib * ECOG Performance status ≤ 1 * Participants must have adequate organ and marrow function as defined below: * Absolute neutrophil count \> 1,500/mcL * Platelets \> 100,000/mcL * Total bilirubin \</= 1.5X normal institutional limits * AST (SGOT) and ALT (SGPT) \</=2.5x normal institutional limits, or \< 5x if liver metastases are present * Creatinine \</= 1.5x normal institutional limits or creatinine clearance \> 50mL/min * Urine Protein:Creatinine ratio of \<1 * Lipase \< 1.5X upper limit of normal * Serum Albumin ≥ 2.8 g/dl * Sexually active subjects must agree to use medically accepted methods of birth control during the course of the study and for 3 months following discontinuation of study treatments (excluding women who are not of child bearing potential and men who have been sterilized). * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Subjects receiving any other standard or investigational anticancer agents, with the exception of somatostatin/octreotide therapy. If patients has received prior cytotoxic chemotherapy, must be at least three weeks since last treatment before first dose of study treatment. * Major surgery or radiation treatment \<4 weeks prior to enrollment. In addition, cannot have received radiation to the thorax or gastrointestinal tract within three months of the first dose of study treatment. * Cannot have received radionuclide treatment within 6 weeks of first dose of study treatment. * High grade or poorly differentiated neuroendocrine tumors * Ongoing immunosuppression with systemic steroids or other immune modulator * Presence of CNS metastatic disease * Uncontrolled hypertension defined by SBP \> 140 or DBP \> 90 despite titration of anti hypertensive medications * No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic atrial fibrillation, or psychiatric illness/social situations that would limit compliance with study requirements. Congestive heart failure or symptomatic coronary artery disease within 3 months prior to enrollment * Cerebrovascular accident within prior 6 months * The subject has a history of clinically significant hematemesis or a recent history of hemoptysis of \> 2.5 mL of red blood or other signs indicative of pulmonary hemorrhage or evidence of endobronchial lesion(s). * The subject has a pulmonary lesion abutting or encasing a major blood vessel. * Previous history of pulmonary embolism or deep venous thrombosis * The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or Coumadin-related agents, heparin, thrombin or FXa inhibitors, and antiplatelet agents (eg, clopidogrel). Low dose aspirin (≤ 81 mg/day), low-dose warfarin (≤ 1 mg/day), and prophylactic Low Molecular Weight Heparin (LMWH) are permitted. * At the time of screening, active peptic ulcer disease or active inflammatory bowel disease (including ulcerative colitis or Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis, or appendicitis. * History of abdominal fistula, gastrointestinal perforation, bowel obstruction, gastric outlet obstruction, or intra-abdominal abscess within six months of study enrollment. * History of GI surgery within the past 28 days. If \>28 days since GI surgery, must have confirmation of complete healing before initiating treatment with study drug. * Other disorders associated with a high risk of fistula formation, including PEG tube placement within 3 months before the first dose of study therapy or concurrent evidence of intraluminal tumor involving the trachea or esophagus. * Other clinically significant disorders such as: * Active infection requiring systemic treatment * Serious non-healing wound/ulcer/bone fracture * History of organ transplant * Concurrent uncompensated hypothyroidism or thyroid dysfunction * History of major surgery within 4 weeks or minor surgical procedures within one week before randomization * The subject has a corrected QT interval calculated by the Fridericia formula \> 500ms within 28 days before randomization. * Severely impaired lung function * Concurrent malignancy (other than non-melanoma skin cancer) diagnosed within the past 3 years or any currently active malignancy * Pregnant women are excluded from this study due to the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with the treatment protocol, breastfeeding should be discontinued if the mother is treated on protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Imaging was performed cycles 2,4,6 every 8 weeks for the first 24 weeks, then every 3rd cycle every 12 weeks until progression or EOT. Median treatment duration was 8 cycles for the Carcinoid cohort and 12.5 cycles for the PNET cohort. Cycle=28 days. | The objective response rate of cabozantinib was evaluated according to RECIST v 1.1 criteria (Response Evaluation Criteria In Solid Tumors v 1.1). Disease was assessed using CT and/or MRI scans. RECIST 1.1 criteria include the following categories of disease response: Complete Response (CR) = disappearance of all target lesions; Partial Response (PR) = 30% or more decrease in the sum of the longest diameter of target lesions; Stable disease (SD) = less than 30% decrease but no more than 20% increase in sum of the longest diameter of target lesions. Objective response rate consisted of CR + PR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Restaging imaging was performed after cycles 2, 4, and 6 (every 8 weeks for the first 24 weeks), then every 3rd cycle (every 12 weeks) until disease progression or end of study treatment. Median follow-up is 89.1 months. Cycle = 28 days. | Progression-free survival was defined as time in months from initiation of treatment until disease progression by RECIST 1.1 criteria or death from any cause. Progressive disease by RECIST 1.1 criteria is defined as at least a 20% increase in the sum of the longest dimensions of target lesions, taking as reference the smallest sum of longest dimensions recorded since the treatment started; the appearance of one or more new lesions; unequivocal progression of existing non-target lesions. |
| Overall Survival (OS) | Median follow-up time of 89.1 months. | Overall Survival (OS) based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Metastatic or Unresectable PNET Patients with pancreatic neuroendocrine tumors receiving cabozantinib
Cabozantinib: 60 mg QD orally in cycles of 28 days | 20 |
| Metastatic or Unresectable Carcinoid Patients with advanced or metastatic carcinoid tumor receiving cabozantinib
Cabozantinib: 60 mg QD orally in cycles of 28 days | 41 |
| Total | 61 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 6 |
| Overall Study | Death | 1 | 1 |
| Overall Study | Physician Decision | 0 | 4 |
| Overall Study | progression/relapse | 14 | 21 |
| Overall Study | prolonged treatment delay | 1 | 1 |
| Overall Study | Withdrawal by Subject | 2 | 8 |
Baseline characteristics
| Characteristic | Metastatic or Unresectable PNET | Metastatic or Unresectable Carcinoid | Total |
|---|---|---|---|
| Age, Continuous | 55 years | 63 years | 60 years |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Sex: Female, Male Female | 8 Participants | 23 Participants | 31 Participants |
| Sex: Female, Male Male | 12 Participants | 18 Participants | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 20 | 3 / 41 |
| other Total, other adverse events | 20 / 20 | 41 / 41 |
| serious Total, serious adverse events | 15 / 20 | 24 / 41 |
Outcome results
Primary
Objective Response Rate (ORR)
The objective response rate of cabozantinib was evaluated according to RECIST v 1.1 criteria (Response Evaluation Criteria In Solid Tumors v 1.1). Disease was assessed using CT and/or MRI scans. RECIST 1.1 criteria include the following categories of disease response: Complete Response (CR) = disappearance of all target lesions; Partial Response (PR) = 30% or more decrease in the sum of the longest diameter of target lesions; Stable disease (SD) = less than 30% decrease but no more than 20% increase in sum of the longest diameter of target lesions. Objective response rate consisted of CR + PR.
Time frame: Imaging was performed cycles 2,4,6 every 8 weeks for the first 24 weeks, then every 3rd cycle every 12 weeks until progression or EOT. Median treatment duration was 8 cycles for the Carcinoid cohort and 12.5 cycles for the PNET cohort. Cycle=28 days.
Population: Response rate by RECIST 1.1 was calculated by including all patients who started study therapy.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Metastatic or Unresectable PNET | Objective Response Rate (ORR) | 3 Participants |
| Metastatic or Unresectable Carcinoid | Objective Response Rate (ORR) | 7 Participants |
Secondary
Overall Survival (OS)
Overall Survival (OS) based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.
Time frame: Median follow-up time of 89.1 months.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Metastatic or Unresectable PNET | Overall Survival (OS) | 37.3 months |
| Metastatic or Unresectable Carcinoid | Overall Survival (OS) | 36.1 months |
Secondary
Progression Free Survival (PFS)
Progression-free survival was defined as time in months from initiation of treatment until disease progression by RECIST 1.1 criteria or death from any cause. Progressive disease by RECIST 1.1 criteria is defined as at least a 20% increase in the sum of the longest dimensions of target lesions, taking as reference the smallest sum of longest dimensions recorded since the treatment started; the appearance of one or more new lesions; unequivocal progression of existing non-target lesions.
Time frame: Restaging imaging was performed after cycles 2, 4, and 6 (every 8 weeks for the first 24 weeks), then every 3rd cycle (every 12 weeks) until disease progression or end of study treatment. Median follow-up is 89.1 months. Cycle = 28 days.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Metastatic or Unresectable PNET | Progression Free Survival (PFS) | 21.1 months |
| Metastatic or Unresectable Carcinoid | Progression Free Survival (PFS) | 17.6 months |